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Vitamin D Analog Calcipotriol Suppresses the Th17
Cytokine–Induced Proinflammatory S100 ‘‘Alarmins’’
Psoriasin (S100A7) and Koebnerisin (S100A15) in
Psoriasis
Zuzana Hegyi1,3, Stephanie Zwicker1,3, Daniela Bureik1, Mark Peric1, Sarah Koglin1,
Aleksandra Batycka-Baran1,2, Jo¨rg C. Prinz1, Thomas Ruzicka1, Ju¨rgen Schauber1,4 and Ronald Wolf1,4
The antimicrobial peptides (AMP) psoriasin (S100A7) and koebnerisin (S100A15) are differently induced in
psoriatic skin. They act synergistically as chemoattractants and ‘‘alarmins’’ to amplify inflammation in psoriasis.
Th17 cytokines are key players in psoriasis pathogenesis and vitamin D analogs feature anti-psoriatic effects;
both of these activities could be mediated through epidermal AMP regulation. We show that supernatants of
cultured psoriatic T cells induce and release psoriasin and koebnerisin from keratinocytes and the Th17
cytokines IL-17A, tumor necrosis factor-a, and IL-22 differently regulate psoriasin and koebnerisin reflecting
their distinct expression pattern in normal and psoriatic skin. IL-17A is the principal inducer of both S100 and
their expression is further amplified by cooperating Th17 cytokines in the micromilieu of psoriatic skin.
Increased extracellular psoriasin and koebnerisin also synergize as ‘‘alarmins’’ to prime epidermal keratinocytes
for production of immunotropic cytokines that further amplify the inflammatory response. Treatment of
psoriatic plaques with the vitamin D analog calcipotriol interferes with the S100-mediated positive feedback
loop by suppressing the increased production of psoriasin and koebnerisin in psoriatic skin and their Th17-
mediated regulation in epidermal keratinocytes. Thus, targeting the S100-amplification loop could be a
beneficial anti-inflammatory approach in psoriasis and other inflammatory skin diseases.
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INTRODUCTION
Psoriatic skin lesions are characterized by increased epidermal
proliferation, abnormal keratinocyte differentiation, and infil-
trating inflammatory cells. The immunopathogenesis involves
a dysregulated interaction between epidermal keratinocytes
and infiltrating inflammatory cells (Lowes et al., 2007).
Important mediators of epidermal–dermal communication are
antimicrobial peptides (AMPs; Harder et al., 2007; Peric et al.,
2008, 2009).
The AMP Koebnerisin (S100A15) was first cloned from
‘‘koebnerized’’ lesional psoriatic skin (Wolf et al., 2003)
and is highly homologous to psoriasin (S100A7), which
has been identified earlier from psoriatic keratinocytes
(Madsen et al., 1991). Both proteins are considered disease
candidate genes that have recently evolved within the
recombinant region of S100 gene clusters on psoriasis
susceptibility locus 4 (PSORS4, epidermal differentiation
complex, chromosome 1q21; Kulski et al., 2003). Despite
their high homology, psoriasin and koebnerisin are differen-
tially regulated by cell types in the skin and have distinct
proinflammatory functions and mechanisms of action.
Psoriasin (S100A7) encodes for a single transcript, whereas
two alternate koebnerisin (S100A15) mRNA-splice variants
have been discovered. Both S100A15-isoforms are differently
expressed in psoriatic skin suggesting regulation through
alternate promoters (Wolf et al., 2003). We aimed to
understand the mechanisms that mediate their differential
regulation in normal skin and induction in psoriasis and how
is this affected by anti-psoriatic vitamin D analogs.
Th17 cytokines are important mediators of psoriatic
inflammation (Boniface et al., 2007; Wilson et al., 2007;
Glaser et al., 2009). The Th17 cytokines IL-17A, tumor
necrosis factor (TNF)-a, and IL-22 differentially regulate
psoriasin and koebnerisin in epidermal keratinocytes and we
identified IL-17A as a major inducer of both S100 in
keratinocytes. Their differential expression is mediated through
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the IL-17A receptor and further amplified by other Th17
cytokines in the micromilieu of psoriatic skin. Th17-induced
psoriasin and koebnerisin act synergistically as ‘‘alarmins’’ on
resident skin cells by upregulating proinflammatory cytokines
in keratinocytes that further amplify the inflammatory
response. Vitamin D/analogs reduce psoriasin and koebnerisin
expression in psoriatic skin, partially by reducing the S100-
stimulating Th17 effect on epidermal keratinocytes, and thus
interfere with the S100-mediated proinflammatory feedback
loop. These finding reveal previously unreported insights into
the Th17-mediated regulation of psoriasin and koebnerisin,
their function as ‘‘alarmins’’ and reveals a yet unknown
anti-inflammatory mechanism of vitamin D analogs.
RESULTS
Psoriasin (S100A7) and koebnerisin (S100A15) are differentially
expressed in psoriasis and distinctly regulated and secreted by
Th17-derived cytokines in keratinocytes
The epidermal AMPs, psoriasin (S100A7) and koebnerisin
(S100A15), have been suggested to contribute to cutaneous
inflammation in psoriasis (Sabat et al., 2007; Wolf et al., 2008);
however, their differential regulation by proinflammatory
pathogenetic factors important in psoriasis has not been
elucidated. Production of psoriasin and koebnerisin was
pronounced in inflamed psoriatic skin (Figure 1a). Both proteins
are secreted at a similarly high rate, but at a different ratio
(psoriasin: 1/3.8 and koebnerisin 1/2.5) by psoriatic keratino-
cytes that might contributes to their distinct intracellular roles
and functions as chemoattractants and alarmins (Wolf et al.,
2010a, 2010b). Although co-upregulated in psoriasis both
highly homologous S100-proteins showed a distinct expression
pattern in the skin. Koebnerisin (S100A15) but not psoriasin
(S100A7) was highly expressed by basal psoriatic keratinocytes
at the epidermal–stroma junction, as well as dendritic and
stromal cells in the dermis. However, both proteins were
markedly induced in the suprabasal epidermis of inflamed
psoriatic skin suggesting an induction in keratinocytes by
proinflammatory T cell–derived stimuli. For further analysis,
supernatants of cultured dermal T cells isolated from lesional
psoriatic skin were used for keratinocyte stimulation. T cell
supernatants induced the expression of psoriasin (S100A7) and
both alternate spliced isoforms of koebnerisin (S100A15) in
keratinocytes to a similar extent (Figure 1b).
Keratinocytes were then stimulated with T cell–derived
Th17 cytokines to compare the differential inducibility of
psoriasin and koebnerisin in the epidermis (Figure 1c and d).
Combined cytokine treatment was superior over exposure to
a single cytokine reflecting the pronounced S100 induction in
the epidermis by Th17 cytokines that are pathophysiologi-
cally increased in the psoriatic skin (Figure 1c). Among the
cytokine compositions analyzed, IL-17A with TNF-a or IL-22
similarly amplified the expression of psoriasin (S100A7) and
koebnerisin (long S100A15 alternate splice variant
(S100A15L)), whereas the alternate spliced short S100A15
variant (S100A15S) isoform followed this pattern to a lesser
extend. Induction of psoriasin and koebnerisin led to a
differential release of both proteins into the keratinocyte
supernatant suggesting distinct mechanisms of secretion in
addition to regulation (Figure 1d). Similarly, IL-17A in
combination with TNF-a or IL-22 had pronounced but
differential effects on psoriasin and koebnerisin release
compared with single cytokines or co-treatment of keratino-
cytes with IL-22 and TNF-a. To understand the differential
regulation of psoriasin and koebnerisin in epidermal keratino-
cytes, we analyzed their sequential induction through single
Th17 cytokines (Figure 2a–c). All individual cytokines induced
psoriasin (S100A7) with IL-17A having a maximal effect at
24hours followed by TNF-a and IL-22 with the same pattern
but to a lesser extend. Koebnerisin (S100A15) paralleled the
psoriasin expression pattern by IL-17A but was induced to a
higher extend compared with S100A7. TNF-a also had a more
pronounced effect on S100A15L expression by keratinocytes
than S100A7 at 24hours. However, S100A15S was not
induced this late but already showed an earlier peak at
6 hours together with S100A15L. IL-22 alone had little effect
on regulating S100A7 or both S100A15-isoforms in keratino-
cytes. Thus, the differential induction pattern of psoriasin and
koebnerisin by individual Th17 cytokines could resemble their
differential expression pattern in the inflamed psoriatic
epidermis. The combined Th17 cytokine milieu in psoriasis may
contribute to their co-upregulation and release by psoriatic
keratinocytes and allows them to synergize as extracellular
chemoattractants and ‘‘alarmins’’.
T cell-derived IL-17A but not TNF-a is the principal inducer of
psoriasin (S100A7) and koebnerisin (S100A15) through IL-17AR
in keratinocytes
The most pronounced psoriasin (S100A7) and koebnerisin
(S100A15) induction was observed after combined treatment
of keratinocytes with IL-17A and TNF-a (Figure 1c and d) and
after exposure to IL-17A alone over time (Figure 2a).
Immunofluorescence staining showed IL-17A immuno-
reactivity (arrow) to epidermal keratinocytes of basal and
suprabasal layers in normal and more pronounced in
psoriatic skin, particularly where koebnerisin is predomi-
nantly expressed (Figure 3a). This suggests that baseline levels
of IL-17A in normal volunteers (Tanasescu et al., 2010; Mei
et al., 2011) and increased IL-17A levels in psoriasis regulate
the differential psoriasin and koebnerisin expression in both
normal tissue and Th17-mediated diseases. To verify the
major role of IL-17A for the epidermal S100 regulation in
psoriasis, keratinocytes were treated with supernatants of
cultured dermal T cells isolated from lesional psoriatic skin in
the presence of IL-17AR blocking antibodies (Figure 3b). The
T cell supernatants induced psoriasin and both alternate
koebnerisin transcripts in keratinocytes to a similar extend.
The upregulation of psoriasin (S100A7) was markedly
attenuated by IL-17AR blocking antibodies and completely
blocked both alternate koebnerisin (S100A15L and S)
transcripts. Similarly, induction of both S100 proteins was
neutralized by blocking the IL-17A receptor when keratino-
cytes were stimulated with IL-17A alone (Figure 3d).
However, adding equal amounts of TNF-a neutralizing
antibody (Ab) to the supernatants of cultured psoriatic dermal
T cells had only a minor blocking effect on expression of
either S100 protein in keratinocytes (Figure 3c). This data reflect
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IL-17A binding to basal epidermal keratinocytes to regulate
koebnerisin as well as to suprabasal cells to induce both S100
proteins in normal and psoriatic epidermis (Figures 1a and 3b, d).
Although IL-17A has a more pronounced effect on
koebnerisin regulation (Figures 2a and 3b, d), IL-17A is a
major key cytokine that regulates both S100 in the psoriatic
epidermis.
The ‘‘alarmins’’ psoriasin (S100A7) and koebnerisin (S100A15)
synergize to regulate proinflammatory cytokines and
antimicrobial peptides in keratinocytes
Psoriasin (S100A7) and koebnerisin (S100A15) were induced
and released by epidermal keratinocytes stimulated with
proinflammatory Th17 cytokines (Figures 1–3). As the
extracellular S100 proteins synergize to mediate inflamma-
tion by attracting leukocytes (Wolf et al., 2008), we next
investigated their contribution to amplify inflammation as
‘‘alarmins’’ through an autocrine loop on keratinocytes.
Keratinocytes stimulated with psoriasin (S100A7) and koeb-
nerisin (S100A15) alone or in combination were analyzed for
induction of proinflammatory mediators and antimicrobial
peptides (Figure 4). Both S100 proteins induced individual
cytokines, and for TNF-a and IL-8 combined treatment with
psoriasin and koebnerisin had an amplifying effect (Figure 4a
and c). Antimicrobial peptides, such as S100A8, were not
affected by psoriasin or koebnerisin, whereas hBD2 appeared
to be suppressed by either S100 and when applied in
combination (Figure 4d–f). As both S100 proteins naturally
appear together in psoriasis, these data indicate that psoriasin
and koebnerisin synergize as ‘‘alarmins’’ to prime epidermal
keratinocytes for enhanced production of immunotropic
cytokines and to regulate other antimicrobial peptides
important in epidermal host defense. These data indicate
that psoriasin (S100A7) and koebnerisin (S100A15) participate
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Figure 1. Psoriasin (S100A7) and koebnerisin (S100A15) are differentially induced and secreted in psoriatic skin and by psoriatic T cell–derived Th17
cytokines in epidermal keratinocytes. (a) Immunofluorescent co-staining of frozen sections of normal and lesional psoriatic back skin stained for psoriasin
(S100A7, green) and koebnerisin (S100A15, red). Nuclei were stained with 40-6-diamidino-2-phenylindole (DAPI; blue). Bar¼ 100mm. (b) Human keratinocyte-
derived HaCaT cells were treated with supernatants from T cells isolated from psoriatic plaques and (c) primary human keratinocytes were treated with IL-17A
(10 ngml1), IL-22 (10 ngml1), and tumor necrosis factor-a (TNF-a; 100 ngml1), alone or in combination. (b, c) Expression of psoriasin (S100A7) and
koebnerisin (S100A15) alternate mRNA isoforms was analyzed after 24 hours by quantitative real-time reverse transcription-PCR. Data are mean±SEM of three
independent experiments performed in triplicate; *Po0.05 determined by Student’s t-test. (d) Immunoblots of supernatants from cultured primary human
keratinocytes using specific antibodies against psoriasin (S100A7) or koebnerisin (S100A15). Numbers show S100 ratios normalized for b-actin from
corresponding lysates. Representative pattern from experiments performed in triplicate. NC, negative control.
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Figure 2. Psoriasin (S100A7) and koebnerisin (S100A15) are differently regulated by Th17-derived cytokines in epidermal keratinocytes. (a–c) Differential
regulation of psoriasin (S100A7) and koebnerisin (S100A15) alternate mRNA isoforms (S100A15L, S100A15S) in primary human keratinocytes after treatment
with (a) IL-17A, (b) tumor necrosis factor (TNF)-a, or (c) IL-22 at indicated concentrations over time and analyzed by quantitative real-time reverse transcription-
PCR. Data are mean±SEM of three independent experiments performed in triplicate; *Po0.05 determined by Student’s t-test. NC, negative control.
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Figure 3. T cell–derived IL-17A binds to normal and psoriatic epidermis and is a principal inducer of psoriasin (S100A7) and koebnerisin (S100A15) in skin
keratinocytes. (a) Immunofluorescent staining of frozen sections of healthy and lesional psoriatic skin stained for IL-17A (yellow) detecting IL-17A bound to
epidermal keratinocytes. Arrow marks IL-17A-producing immunocytes in the dermis of psoriatic skin. Bar¼ 100mm. (b, c) Human keratinocyte-derived HaCaT
cells were treated with supernatants from T cells isolated from psoriatic plaques in the presence of (b) IL-17AR neutralizing antibody (Ab) or (c) tumor necrosis
factor (TNF)-a neutralizing Ab (golimumab, Simponi) compared with non-immune IgG. (d) Primary human keratinocytes were treated with IL-17A (10 ngml1)
in the presence of IL-17AR blocking Ab compared with non-immune IgG. Cells were harvested after 24 hours and S100 transcript levels were analyzed by
quantitative real-time reverse transcription-PCR. Data are mean±SEM of three independent experiments from individual patients performed in triplicate;
*Po0.05 determined by Student’s t-test.
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in an amplification loop involving innate epidermal and
adaptive immunity as it has been shown for it ancestral single
mS100a7a15 mouse ortholog (Wolf et al., 2010a).
Treatment with the vitamin D analog calcipotriol suppresses
psoriasin (S100A7) and koebnerisin (S100A15) expression in
psoriasis
Vitamin D analogs are widely used as topical therapeutics for
psoriasis but their anti-inflammatory mechanisms have not yet
been fully understood (Fogh and Kragballe, 1997). Because of
the synergistic role of psoriasin and koebnerisin as chemoat-
tractants (Wolf et al., 2008) and ‘‘alarmins’’ (Figure 4) in the
pathogenesis of psoriasis, their regulation in psoriatic plaques
after topical treatment with anti-psoriatic calcipotriol was
assessed (Figure 5a). Skin sections of psoriatic plaques showed
a reduced epidermal thickening and further a decreased
psoriasin and koebnerisin production after calcipotriol treat-
ment (Figure 5a and b). The downregulation of psoriasin
(S100A7) transcripts and both alternate RNA isoforms of
koebnerisin (S100A15) by calcipotriol suggests a transcrip-
tional regulation through vitamin D in the psoriatic skin
(Figure 5c). In support, S100-immunoblot analysis from skin
biopsies demonstrated the increased production of psoriasin
and koebnerisin in psoriasis, which was suppressed after
treatment of psoriatic plaques with calcipotriol (Figure 5d).
1,25D3 antagonizes the Th17 cytokine–mediated induction of
psoriasin (S100A7)/koebnerisin (S100A15) subfamily in
keratinocytes and suppresses the S100-mediated
proinflammatory loop in psoriasis
As the vitamin 1,25D3 analog calcipotriol suppressed
psoriasin (S100A7) and koebnerisin (S100A15) induction in
the psoriatic epidermis (Figure 5), the effect of vitamin
1,25D3 on Th17 cytokine–mediated regulation in human
keratinocytes was analyzed. Mimicking a Th17 milieu typical
for psoriasis, keratinocytes were stimulated with a combina-
tion Th17 cytokines that was able to amplify both psoriasin
and koebnerisin transcripts (Figure 6a). The increased
expression of both S100 in keratinocytes was attenuated in
the presence of vitamin 1,25D3 with a pronounced effect on
the S100A7 and S100A15L transcripts compared with
S100A15S. Treatment of epidermal cells with vitamin
1,25D3 was also able to reduce the induction of psoriasin
(S100A7) and koebnerisin (S100A15) by IL-17A alone
showing an effect on the principal inducer of these two
S100 proteins (Figure 6c,d). The inhibitory effect of vitamin
1,25D3 on psoriasin and koebnerisin production could be
demonstrated by immunoblot analysis of keratinocytes
stimulated by IL17A alone and by IL-22 plus TNF-a (Figure 6b),
but not for other Th17 cytokines in combination. Together,
data suggest that the increased S100 production by epidermal
keratinocytes in a complex Th17 milieu is only slightly affected
by direct vitamin D action on keratinocytes. However,
vitamin D analogs inhibit infiltrating immune cells that create
the S100-inducing Th17 milieu in psoriasis and could explain
the marked suppression psoriasin and koebnerisin expression
in psoriatic plaques after calcipotriol treatment (Figure 5; van
der Vleuten et al., 1996; Ikeda et al., 2010). Thus, vitamin D
analogs are able to interfere with the inflammatory feedback
loop in psoriatic skin by suppressing the Th17-induced
proinflammatory functions of psoriasin and koebnerisin as
chemoattractants and ‘‘alarmins’’ (Figure 6e).
DISCUSSION
Psoriasin (S100A7) and koebnerisin (S100A15), first identified
in psoriasis, are highly homologous proteins with distinct
functions and expression patterns and encode a innate
subfamily within the psoriasis susceptibility locus 4 (PSORS4,
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Figure 4. The ‘‘alarmins’’ psoriasin (S100A7) and koebnerisin (S100A15) synergize to regulate proinflammatory cytokines and antimicrobial peptides in
epidermal keratinocytes. (a–f) Primary human keratinocytes were treated with psoriasin (S100A7, 100 ngml1) and koebnerisin (S100A15, 100 ngml1) alone or
in combination and expression of indicated proinflammatory mediators and antimicrobial peptides was analyzed by quantitative real-time reverse transcription-
PCR after 1 hour. Data are mean±SEM of three independent experiments performed in triplicate; *Po0.05 determined by Student’s t-test. TNF, tumor necrosis
factor.
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chromosome 1q21; Madsen et al., 1991; Wolf et al., 2003).
Beside their synergistic antimicrobial activity in the skin
(Glaser et al., 2005; Bu¨chau et al., 2007), both proteins are
chemoattractants for leukocytes through distinct mechanisms
and to amplify inflammation (Wolf et al., 2008, 2010b). In
addition, we show that psoriasin and koebnerisin prime
epidermal keratinocytes for an enhanced production of
immunotropic cytokines, such as TNF-a, IL-6, and IL-8, and
suppressing other AMPs. Their role as ‘‘alarmins’’, which to
our knowledge is previously unreported, is consistent with an
evolving understanding of AMPs that can also function as
self-danger molecules important for innate and adaptive
immunity and is evolutionary conserved in the corresponding
mS100a7a15 protein (Harder et al., 2007; Wolf et al., 2010a).
As psoriasin and koebnerisin have synergistic but distinct
functions and expression patterns, it is important to dissect their
differential regulation (Sabat et al., 2007; Eyerich et al., 2009).
Th17 cytokines secreted by psoriatic T cells are important
players in psoriasis pathogenesis (Boniface et al., 2007;
Wilson et al., 2007; Lowes et al., 2008; Glaser et al., 2009;
Kagami et al., 2010) and investigated Th17 cytokines
differentially induce psoriasin (S100A7) and koebnerisin
(S100A15) in keratinocytes. Despite the differences, S100A7
and S100A15L transcripts showed a similar regulation pattern
compared with the alternate S100A15S isoform that was
mostly induced at an earlier time point and to a lesser extent
upon an inflammatory stimulus. Their differential regulation
pattern is likely due to evolutionary conserved promoters at
exon 1 similarly driving the S100A7 and S100A15L
transcripts, whereas S100A15S is distinctly regulated through
an alternate promoter at exon 2 (Wolf et al., 2003). Induction
of psoriasin and koebnerisin led to a differential release of
both proteins into the keratinocyte supernatant also suggest-
ing distinct mechanisms of secretion. Data indicate that
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psoriasin and koebnerisin are differentially induced by
soluble mediators of Th17-differentiated lymphocytes, which
reflects the differential expression pattern in the psoriatic
epidermis (Wolf et al., 2007; Glaser et al., 2009). Further, the
IL-17A immunoreactive pattern in the psoriatic epidermis
correlates with that in normal skin, suggesting that baseline
levels of IL-17A in normal volunteers may regulate the
differential psoriasin and koebnerisin expression under
physiological conditions in normal skin (Tanasescu et al.,
2010; Mei et al., 2011).
IL-17A is a central cytokine in psoriasis pathogenesis and
correlates with disease severity (Harper et al., 2009;
Chiricozzi et al., 2011). It is secreted as a homodimer and
activates its receptor IL-17AR, which leads to induction of
cytokines and chemokines, including TNF-a, IL-1b, IL-8, and
IL-6 in target cells (van Beelen et al., 2007). Inhibition of
the IL-17A receptor blocked the induction of both psoriasin
(S100A7) and koebnerisin (S100A15) in keratinocytes
stimulated with supernatant from psoriatic T cells. However,
IL-17A exerts a more pronounced effect on koebnerisin
regulation than on that of psoriasin suggesting involvement of
additional factors that contribute to their expression in
psoriasis. However, blocking TNF-a by golimumab (Simponi)
was much less effective reducing the expression of psoriasin
and koebnerisin in keratinocytes when used at same
concentrations. These data identify IL-17A as a principal
inducer of psoriasin and koebnerisin together with cooperat-
ing Th17 cytokines that contribute to the differential
regulation pattern of psoriasin and koebnerisin in the normal
and psoriatic epidermis. Similarly, a differential regulation of
psoriasin (S100A7) and koebnerisin (S100A15) in keratino-
cytes by Th1 and Th2 cytokines has been previously observed
(Glaser et al., 2005; Wolf et al., 2007). Together, data suggest
that infiltrating immune cells participate in the upregulation
of psoriasin and koebnerisin in psoriatic epidermis with IL-
17A being their key inducer. Their differential induction and
release may in turn attract additional immunocytes through
their synergistic chemotactic activity and further induce the
expression of proinflammatory cytokines as ‘‘alarmins’’ in
keratinocytes amplifying an proinflammatory feedback loop
in psoriasis (Wolf et al., 2008, 2010a, 2010b). An evolu-
tionary conserved proinflammatory feedback loop has been
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reported for the corresponding mouse S100a7a15 ortholog of
psoriasin and koebnerisin (Wolf et al., 2010a).
Vitamin D analogs are a hallmark in the treatment of
psoriasis but the mechanisms behind their anti-psoriatic
actions are not fully understood (Fogh and Kragballe, 1997).
In contrast to a previous report that could not show a
psoriasin regulation in psoriasis by calcipotriol (Peric et al.,
2009), we demonstrate that calcipotriol normalizes the
psoriatic phenotype and is accompanied by a decreased
expression and production of psoriasin (S100A7) and
koebnerisin (S100A15) in the psoriatic skin. S100 proteins
are regulated by NF-kB and calcipotriol blocks NF-kB
activation and might influence IL-17A receptor expression
(Riis et al., 2004; Sinha et al., 2008). Thus, calcipotriol might
decrease S100 directly by blocking IL-17 receptor and NF-kB
signaling in keratinocytes. Further, calcipotriol lowers the
number of proinflammatory T cells to the skin resulting in
decreased IL-17A levels able to induce S100 in keratinocytes
(van der Vleuten et al., 1996; Ikeda et al., 2010). We further
show that vitamin 1,25D3 can interfere with the induction of
both psoriasin and koebnerisin in keratinocytes stimulated
with the principal inducer IL-17A or combined IL-22 and
TNF-a cytokines. But in a complex Th17 environment,
vitamin 1,25D3 has a minor direct effect on psoriasin and
koebnerisin regulation in keratinocytes; however, the com-
bined interference with infiltrating immunocytes could
influence psoriasin and koebnerisin levels in psoriatic skin.
Data provide new insights into the anti-inflammatory effects
of calcipotriol by its combined targeting of inflammatory S100
as both chemoattractants and ‘‘alarmins’’ that are important in
the proinflammatory feedback loop driving the pathogenesis of
psoriasis and other chronic inflammatory diseases.
MATERIALS AND METHODS
Patients and skin samples
All treatments and sample acquisitions were approved by the
local ethical committee (Faculty of Medicine, Ludwig-Maximilian
University Munich, Germany). The study was conducted according
to the Declaration of Helsinki Principles. For all procedures,
informed patient’s written consent was obtained. Patients did not
receive topical therapy for at least 4 weeks before entering the study.
Four-millimeter punch biopsies were taken from a marker psoriatic
plaque from the patient’s back before treatment with a topical
calcipotriol preparation (LEO Pharma, Neu-Isenburg, Germany)
containing ointment (0.005%; applied twice daily) and 5–7 days
after treatment onset. Lesional skin biopsies were compared with
healthy skin. The tissues were subjected to RNA extraction or snap
frozen in liquid nitrogen for immunofluorescence staining.
Human keratinocyte cell culture and stimulation
Human epidermal keratinocytes were grown in EpiLife cell culture
medium (Cascade Biologics, Portland, OR) containing 0.06mM
calcium and 1 EpiLife defined growth supplement at 37 1C under
standard tissue culture conditions. Stock cultures were maintained for
up to six passages in this medium with the addition of 10mgml1
gentamicin and 0.25mgml1 amphotericin B. HaCaT keratinocytes
were cultured in DMEM supplemented with 10% fetal bovine serum,
50Uml1 penicillin and 50mgml1 streptomycin (PAA Laboratories,
Pasching, Austria). Subconfluent keratinocyte cultures were stimulated
with 1,25-dihydroxyvitamin D3 (1,25D3; 10
9
M; Sigma, Steinheim,
Germany), IL-17A (10ngml1; R&D Systems, Wiesbaden, Germany),
IL-22 (10ngml1, R&D Systems), TNF-a (100ngml1, Biomol, Hamburg,
Germany) for 24 hours. When exposed to S100 proteins, S100A7
(psoriasin) and S100A15 (koebnerisin) were used at 100 ngml1 for
1 hour. For blockade of the IL-17AR or TNF-a, a monoclonal mouse
anti-human IL-17AR Ab (5mgml1; R&D Systems) or a TNF-a-neu-
tralizing Ab (golimumab, Simponi, 5 mgml1; Centocor B.V., the
Netherlands) was added 2hours before stimulation with supernatants
derived from psoriatic T cells or IL-17A (10ngml1; R&D Systems).
Isolation of T cells and culture
Small, spindle-shaped skin specimens of B1 cm length were
obtained from psoriatic plaques. Dermis and epidermis were
dissociated from each other following treatment with dispase
(2.5Uml1; Roche, Mannheim, Germany) at 4 1C for 12 hours as
previously described (Prinz et al., 1994). Epidermis and dermis were
cut up into small fragments, and T cells were allowed to emigrate
from the tissue. Dermal T cells were cultivated at a density of 105
cells per ml in RPMI 1640 medium (PAA Laboratories) in the
presence of 5Uml1 recombinant human IL-2 (Roche) without
additional stimuli. T cell supernatants were harvested after 7 days of
cultivation (Prinz et al., 1994) and used for subsequent in-vitro
stimulation experiments.
Quantitative real-time reverse transcription-PCR
Total RNA (1mg) extracted from cells or skin samples using TRIzol
(Invitrogen, Darmstadt, Germany) was reversely transcribed using
DyNAmo complementary DNA Synthesis Kit (Finnzymes, Espoo,
Finland) according to the manufacturer’s instructions. Complemen-
tary DNA was analyzed by the standard SYBR green fluorescein
RQPCR detection system LightCycler 2.0 system (Roche). Resulting
CT values with primers used (Supplementary Table S1 online) were
normalized using the deltaCT method (Wolf et al., 2009b). All
analyses were performed in triplicate from two to three independent
cell stimulation experiments.
Immunofluorescence staining and immunoblotting
Immunofluorescence staining was performed on serial 5-mm frozen
sections of human normal and psoriatic skin fixed in acetone. The
sections were blocked in 10% normal goat serum, and incubated
overnight with anti-S100A15 (5mgml1), anti-S100A7 (10 mgml1;
Abcam, Cambridge, UK) or anti-IL-17A (4mgml1; Santa Cruz
Biotechnology, Heidelberg, Germany; Wolf et al., 2009a). The
sections were then incubated with Alexa Fluor 647 goat anti-rabbit
IgG (Hþ L) highly cross-adsorbed Ab (Invitrogen) and with TRITC
conjugated goat anti-mouse Ab (Dianova, Hamburg, Germany)
diluted in 10% normal goat serum and incubated for 1 hour at room
temperature in a dark humidified chamber. Staining with secondary
antibodies only was performed as a negative control. Sections were
overlaid with 40-6-diamidino-2-phenylindole (ProLong Gold antifade
reagent, Invitrogen). Images of fluorescent stained tissues were
recorded using a 12-bit CCD digital camera PCO PixelFly (PCO,
Kelheim, Germany) on a fluorescent microscope Zeiss ImagerZ1
(Zeiss, Jena, Germany). Production of psoriasin and koebnerisin was
separately quantified in the skin sections using Image J 1.44
(National Institutes of Health, Bethesda, MD). Immunoblotting was
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performed as previously described (Wolf et al., 2010a). In brief,
keratinocyte culture supernatants, skin, or keratinocyte lysates
(15 mg) were prepared using 1% Triton-containing lysis buffer (Cell
Signaling, Frankfurt, Germany). Proteins were separated using a
12% SDS-polyacrylamide gel, transferred to reinforced nitrocellu-
lose membranes and incubated with blocking buffer (Tris buffered
saline, pH 7.4, with 5% milk, 0.1% Tween 20) for 30minutes,
primary Ab (anti-hS100A15, 1 mgml1; anti-hS100A7 Ab, 1 mgml1;
anti-b actin, 1:20,000 Chemicon, Temecula, CA) overnight, and
secondary Ab for 1 hour with several washes (TBS, pH 7.4, 0.1%
Tween 20) between incubations.
Statistical analysis
All statistical analyses were performed using GraphPad Prism 4.0.
(GraphPad Software, La Jolla, CA). Student’s t-test was used to
calculate statistical differences. Values of Po0.05 were considered
significant and all data are displayed as means±SEM.
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